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The immunovirological outcome of lopinavir/ritonavir was evaluated in 70 antiretroviral-
experienced HIV patients; at baseline, median CD4+ cell count was 218 cells/mm3 and median
plasma viraemia 4.58 log10 copies/mL. After 12 months, we observed an increase in CD4+ cell
count to 322 cells/mm3 (P = 0.0001) and a decrease in plasma viraemia to 2.35 log10 copies/mL
(P = 0.0001). Four patients discontinued lopinavir/ritonavir during observation. Among meta-
bolic parameters, only triglyceride concentrations increased during treatment (P = 0.02).
Twenty-six patients had a genotypic resistance test at baseline; four had ≥6 mutations known to
reduce susceptibility to lopinavir/ritonavir. Undetectable plasma viraemia was obtained only in
patients with ≤5 mutations (61.9%).
Introduction
Antiretroviral therapy containing protease inhibitors (PIs) for
HIV-1-infected patients is often associated with a dramatic
decline in plasma viraemia as well as an improvement in
immunological status; in patients previously treated with
several other antiretroviral drugs, this outcome is rarely
obtained. Lopinavir/ritonavir (LPV/RTV, Kaletra), a second
generation PI with a favourable resistance profile, is an attract-
ive therapeutic option in patients with multiple failures to
other agents. However, at the moment only few data are avail-
able on its use in field practice, as most data are taken from
clinical trials.1,2
The aim of our retrospective study is to describe the
immunological and virological outcome of a switch to an
LPV/RTV-containing regimen in PI-experienced patients, to
relate it to the resistance profile at baseline and to assess the
tolerability of the new regimen.
Materials and methods
The study population was retrospectively selected from among
the patients who started an LPV/RTV-containing regimen
at our Institute from September 2000 to March 2002; those
who showed a viral load (VL) > 3 log10 copies/mL while on
highly active antiretroviral therapy (HAART) and with a
follow-up of at least 3 months were included. HIV-RNA
levels were measured using the branched chain DNA (b-DNA)
technique (Chiron, Inc.; detection limit 50 copies/mL).
Primary endpoints were virological failure (a decrease in
HIV-RNA of <0.5 log10 copies/mL) and immunological
failure (a return of CD4+ cell count to baseline values) after at
least 3 months of treatment. Whenever possible, a genotypic
resistance test (Visible Genetics, Trugene, Toronto, Ontario,
Canada) was carried out at baseline. The virological outcome
was also analysed in relation to the presence or absence of
LPV-related mutations at baseline (L10I, K20R, L24I, M46I,
F53L, I54V, L63P, A71V, V82A, I84V and L90M).3,4 The
course of HIV-RNA and CD4+ cell count as well as of glucose
(normal range 80–110 mg/dL), triglycerides (normal value
<180 mg/dL) and total serum cholesterol (normal value
<190 mg/dL) in fasting conditions were also evaluated.
Finally, any change in the salvage regimen and its reasons
were also recorded.
We carried out a statistical analysis using the Friedman
non-parametric test to evaluate the course of viral load and
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CD4 count at different times. A Cox regression model in an
intention-to-treat multivariate analysis was carried out to
identify any predictor of virological failure in our cohort. The
variables included in the model were: gender, age, risk factors
for HIV infection, CDC stage, CD4 counts and HIV-RNA at
baseline, presence of non-nucleoside reverse transcriptase
inhibitors (NNRTIs) in the LPV-containing regimen, and
number of PIs, nucleoside reverse transcriptase inhibitors
(NRTIs) and non-nucleoside reverse transcriptase inhibitors
(NNRTIs) previously failed. For all the analyses, SPSS ver-
sion 11.0 (SPSS Inc., Chicago, IL, USA) for Microsoft Win-
dows was used.
Results
Patients were mostly men (n = 52, 74.3%), with a median age
of 40 years (range 29–67); 24 (34.3%) were classified as CDC
stage C. All patients were on HAART when switching to
LPV/RTV. Most of the patients (n = 39, 55.7%) had already
experienced six or more regimens; only three patients (4.3%)
were at their first failure. The median period of the last
regimen was 368 days (range 23–1359). In the majority of
cases, their last regimen included two NRTIs plus 1–2 PIs
(n = 38, 54.3%); 19 patients (27.1%) switched from a regimen
containing one NNRTI plus 1–2 PIs, and 13 patients (18.6%)
switched from an NNRTI-containing HAART. All the
patients had previously failed a PI-containing regimen. Eight
patients (11.4%) switched to LPV/RTV both because of viro-
logical failure and because of toxicity to the previous regimen
(two for renal failure, two for gastrointestinal intolerance,
one for cutaneous rash, one for hepatic failure, one for lypo-
dystrophy and one for paraesthesia). LPV/RTV was used in
combination with two NRTIs in 47 patients (67.1%), with one
NRTI and one NNRTI in 13 patients (18.6%), with three
NRTIs in five patients (7.1%) and with two NRTIs and one
NNRTI in five patients (7.1%). Moreover, seven patients
(10%) added two new (never used) drugs to the LPV/RTV-
containing regimen (four added two new NRTIs, and three
added one new NRTI and one new NNRTI), 19 patients
(27.1%) added one new NRTI and 12 (17.1%) added one new
NNRTI to the regimen.
Figure 1. Virological (top panel) and immunological (bottom panel) outcomes during follow-up.
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At baseline, median CD4+ cell count was 218 cells/mm3
(range 3–581) and median plasma viraemia was 4.58 log10
copies/mL (range 3.51–5.77). Overall, the median CD4+
cell count increased steadily during the follow-up, with a
statistically significant increase (baseline versus month 3:
P = 0.0001; baseline versus month 12: P = 0.02) (Figure 1,
bottom panel). Concomitantly, we observed a progressive
median statistically significant decrease in plasma viraemia
(baseline versus month 3: P = 0.0001; baseline versus
month 12: P = 0.0001) (Figure 1, top panel). The percentage
of undetectable plasma viraemia was 14.5% (10/69), 39.4%
(26/66), 47.3% (26/55) and 51.8% (14/27) at months 1, 3, 6
and 12, respectively.
During a median follow-up of 329 days (range 95–587),
eight (11.4%) patients developed virological, seven (10%)
immunological and five (7.1%) immunovirological failure;
median time to failure was 196 days (range 95–328).
For metabolic parameters, we observed an increase in the
median triglyceride serum levels starting from the first month
(baseline 208 mg/dL, 1st month 332 mg/dL, 12th month
289 mg/dL; P = 0.02); the other parameters (serum choles-
terol and glycaemia) did not show any significant changes.
None of the variables included in the Cox regression model
were found to be independently associated with virological
failure (data not shown).
Four patients (5.7%) stopped LPV/RTV during the obser-
vation period; three for hepatotoxicity and one for immuno-
virological failure. Two of the three patients who stopped
LPV/RTV because of hepatic toxicity died with cirrhosis 28
and 264 days after stopping; both patients had hepatitis C
virus/hepatitis B virus co-infection. No other patients died or
developed an AIDS-defining illness during follow-up.
We then analysed the outcome of the 26 patients (37.1%)
who had a genotypic resistance test at baseline. Twenty-two
(84.6%) carried <6 mutations and four (15.4%) ≥6 mutations
known to be associated with a reduced susceptibility to
LPV/RTV.
Figure 2 shows the course of HIV-RNA in relation to the
presence or absence of at least six LPV/RTV-related mutations.
In the group with <6 mutations, median plasma viraemia
showed a dramatic decline during the first 3 months of follow-
up; 13/21 (61.9%) patients reached undetectable plasma
viraemia from the third month, whereas in the group of
patients with ≥6 mutations, median plasma viraemia declined
during the first month, but it slowly increased thereafter. None
of the patients in this last group experienced an undetectable
plasma viraemia during the follow-up.
Conclusions
The small number of patients and the 1 year long follow-up
are obviously a limit when drawing definite conclusions.
Despite these limitations some points need to be discussed.
First of all, our results confirm5,6 in a clinical setting that the
use of LPV/RTV as part of a salvage therapy in patients
previously treated with several antiretroviral drugs allows a
substantial increase in CD4+ cell count and a sustained
decline in plasma viraemia. LPV/RTV-containing regimens
were usually well tolerated: only 5.7% of patients stopped
because of toxicity; hypertriglyceridaemia was the most
Figure 2. Virological outcome in relation to the number of mutations at baseline. Open squares indicate patients with ≥6 mutations at baseline
(n = 1–4); open circles indicate patients with <6 mutations at baseline (n  = 8–22).
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important metabolic modification observed; nevertheless, a
longer follow-up is required to improve evaluation of other
possible metabolic modifications. In those patients who har-
boured multiply resistant viruses we observed only a transient
virological response: the number of mutations before using
LPV/RTV seems to be related to virological response in the
medium to long term.
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